PDSB News and Press, PDS Biotechnology Corporation From 05/02/24

2024-05-02 08:25:25 ET More on PDS Biotechnology PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade) Read the full article on Seeking Alpha For further details see: PDS Biotechnology names Stephan Toutain as COO

PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious...

2024-04-29 10:00:00 ET Summary PDS Biotechnology is shifting its focus to a triplet therapy for HPV-positive cancers instead of pursuing approval for PDS0101 alone. The company's pivot raises concerns about potential delays and the need for additional funding. PDSB has enough ...

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial PRINCETON, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq...

2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53.  Positive data ...

2024-03-27 12:17:02 ET PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Conference Call March 27, 2024 08:00 a.m. ET Company Participants Dr. Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Dr. Kirk Shepard - Chief Medical ...

2024-03-27 07:31:30 ET More on PDS Biotechnology PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk Seeking Alpha’s Quant Rating on PDS Biotechnology ...

Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC,...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

2024-03-26 13:47:57 ET More on PDS Biotechnology PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk Seeking Alpha’s Quant Rating on PDS Biotechnology ...